A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease.This study will look into how different and how well groups of people with high chances of developing the disease respond to the study medicine.All data for this study will be anonymously extracted from data already entered in RCC Registry which is owned by Turkish Oncology Group Association (TOGD).This study will pull out records from the Registry between 01-Mar-2019 and 30-Oct-2022 that belongs to people:who are Turkish citizenswho are older than 18 yearswho were found out to have mRCCwho received sunitinib as the first line treatment after finding out the cause for the diseaseThis study will look at the responses, experiences and how long the patients use the study medicine sunitinib.

Inclusion Criteria:Being a Turkish citizen.Being older than 18 years-old.Being clinically diagnosed with mRCC and treated.Being treated with Sunitinib in first lineExclusion Criteria:Patients whose treatment was initiated but excluded from follow-up for any reason.